bances have one common clinical manifestation, namely, premature coronary artery disease. Patients with Down's syndrome have an additional copy of the gene that codes for cystathionine synthase, thus giving them double the amount of this enzyme.³ The result is that they have a much lower than normal homocysteine concentration. Patients with Down's syndrome have been noted as being remarkably free from coronary artery disease.

It has been over two decades since the publication of the original animal work of McCully and Wilson⁵ who proposed the homocysteine theory of arteriosclerosis. After being ignored for many years, homocysteine has finally re-emerged as a risk factor for the development of human atherosclerosis. Although it is "the new player in the field of coronary risk",² homocysteine will become an increasingly important player that can no longer be ignored in the modern-day management of patients with coronary artery disease.

TSUNG O CHENG
Professor of Medicine,
The George Washington University,
Washington, DC 20037, USA

- 1 Lolin YI, Sanderson JE, Cheng SK, Chan CF, Pang CP, Woo KS, et al. Hyperhomocysteinemia and premature coronary artery disease in the Chinese. *Heart* 1996;76:117-22.
- 2 Montalescot G. Homocysteine: the new player in the field of coronary risk [editorial]. *Heart* 1996;76:101-2.
- 3 Scott J, Weir D. Homocysteine and cardiovascular disease. *Q J Med* 1996;89:561-3.
- 4 Scott JM, Weir DG. Folate/vitamin B12 interrelationships. *Essays in Biochemistry* 1994;28:63-72.
- 5 McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. *Atherosclerosis* 1975;22:215-27.

This letter was shown to the authors, who reply as follows:

SIR,—Professor Cheng indicates that: (1) patients with genetic defects (cystathionine β synthase (CBS) and 5,10-methylenetetrahydrofolate reductase) have high plasma concentrations of homocysteine and premature coronary artery disease (CAD), as confirmed again by Lolin's paper; and (2) patients with Down's syndrome have a high CBS activity (the CBS gene is located on chromosome 21) and subsequently low concentrations of homocysteine resulting in a low incidence of CAD.

The high CBS activity and the low plasma concentration of homocysteine in Down's syndrome patients have been known for a long time¹⁻³ and, in 1977, Murdoch described Down's syndrome as a human model free from atheroma.⁴ Thus, the remarks of Professor Cheng are correct, although not new. The remaining question is the possible causal relationship between the genetic abnormality and the weak incidence of CAD in Down's syndrome patients. The latter is still controversial because of the reduced life expectancy and other interfering factors. Finally, authors have also reported "normal" concentrations of homocysteine in Down's syndrome patients.⁵ I think that we need more data to relate the gene abnormality to a low incidence of CAD in Down's syndrome patients.

G MONTALESCOT
Groupe Hospitalier Pitié-Salpêtrière,
47-83 Boulevard de l'Hôpital, 75651 Paris,
Cedex 13, France

- 1 Chadeaux B, Rethone MO, Raoul O, Ceballos I, Poissonnier M, Gilgenkranz S, et al. Cystathionine β synthase: gene dosage effect in trisomy 21. *Biochem Biophys Res Commun* 1985;128:40-4.
- 2 Skovby F, Krassikoff N, Franke U. Assignment of the gene for cystathionine synthase to chromosome 21 by somatic cell hybrids. *Hum Genet* 1984;65:291-4.
- 3 Brattstrom L, Englund E, Brun A. Does Down syndrome support homocysteine theory of arteriosclerosis? *Lancet* 1987;i:391.
- 4 Murdoch JC, Rodger JC, Rao SS, Fletcher CD, Dunnigan MG. Down syndrome an atheroma free model? *BMJ* 1977;ii:226-8.
- 5 Brattstrom L, Israelsson B, Tengborn L, Hultberg B. Homocysteine, factor VII and antithrombin III in subjects with different gene dosage for cystathionine beta synthase. *J Inher Metab Dis* 1989;12:475-82.

Hypereosinophilic syndrome: endomyocardial fibrosis

SIR,—We were interested to read Pitt and colleagues' description of their patient with endomyocardial fibrosis.¹ At the end of their discussion they mention that future management of their patient will involve assessment for cardiac transplantation. However, they do not mention endocardectomy, which we regard as the operation of choice in suitably symptomatic patients. The operation consists of endocardial decortication, essentially a coring out of the fibrous tissue, with atrioventricular valve replacement or repair. We recently had a 40 year old female Lebanese patient with endomyocardial fibrosis affecting both ventricles who underwent biventricular endocardectomy with tricuspid valve annuloplasty. Although she had a slow recovery requiring inotropic support for five days, and was eventually discharged on the 20th postoperative day, symptomatically she was much improved.

Endocardial decortication for this disease was introduced by Dubost *et al* in 1973² and there are now several operative series in the literature.³ Most series report a hospital mortality rate of 20%, most often secondary to low cardiac output. For those who survive the operation 75% are alive after five years, and in the majority of cases there is good clinical improvement.³ Untreated, patients with endomyocardial fibrosis usually die within three years. Most patients in the reported series were in NYHA class III or IV and it is likely that operative mortality will be less if patients undergo surgery at an earlier stage.

JAMIL MAYET
PRAPA KANAGARATNAM
CHRISTOPHER LINCOLN
PAUL OLDERSHAW
Royal Brompton Hospital,
Sydney Street,
London SW3 6NP, United Kingdom

- 1 Pitt M, Davies MK, Brady AJB. Hypereosinophilic syndrome: endomyocardial fibrosis. *Heart* 1996;76:377-8.
- 2 Dubost C, Prigent C, Gerbaux A, Maurice P, Passeleco J, Rulliere R, et al. Surgical treatment of constrictive fibrous endocarditis. *J Thoracic Cardiovasc Surg* 1981;82:585-91.
- 3 Da Costa FDA, Moraes CR, Rodrigues JV, de Mendonca JT, Andrade JC, Buffolo E, et al. Early surgical results in the treatment of endomyocardial fibrosis. A Brazilian co-operative study. *Eur J Cardiothorac Surg* 1989;3:408-13.

Endomyocardial fibrosis in Egypt: an illustrated review

SIR,—We read with great interest the paper on endomyocardial fibrosis (EMF) by

Rashwan *et al.*¹ Their association of cases with hepatosplenic schistosomiasis, which was felt to be involved in the production of EMF rather than just the coincidence of two diseases, has been reported previously. We published a case report in 1973 making the suggestion of a pathogenetic relation of schistosomiasis to EMF.² Another case report illustrating the association was published more recently.³

JH ANTONIO
MC DINIZ
D MIRANDA
HL SOARES
EJC MELO
Department of Internal Medicine,
Faculdade de Ciências Médicas Belo Horizonte,
Minas Gerais—Brazil
D MIRANDA
A NUNES
Department of Pathology,
Santa Casa de Belo Horizonte,
Minas Gerais—Brazil

- 1 Rashwan MA, Aymman M, Ashour S, Hassanin MM, Zeina AAA. Endomyocardial fibrosis in Egypt: an illustrated review. *Br Heart J* 1995;73:284-9.
- 2 Antonio JH, Diniz MC, Miranda D, Nunes A, Soares HL, Melo EJC. Endomyocardial fibrosis and cardiopulmonary schistosomiasis. *Arg Bras Cardiol* 1973;26:569-75.
- 3 Victor EG, Lira V, Arruda A, Monteiro I, Lima R. Granulomas cardíacos, ovos de Schistosoma e fibrose endomiocárdica. *Arg Bras Cardiol* 1996;67:259-61.

Deterioration in renal function with enalapril but not losartan in a patient with renal artery stenosis in a solitary kidney

SIR,—Angiotensin-converting enzyme (ACE) inhibitors are widely used in the treatment of hypertension and heart failure. However, when given to patients with bilateral renal artery stenosis or unilateral stenosis in a solitary kidney, they can cause renal impairment that is usually reversible on stopping the drug.¹ Recently, an angiotensin II (AII) receptor blocker (losartan) was introduced for the treatment of hypertension. We report a patient with severe hypertension and apparent heart failure who developed renal impairment with an ACE inhibitor but not with the AII receptor antagonist.

A 73 year old man with a previous history of severe hypertension was admitted to hospital with symptoms and signs of biventricular failure. Blood pressure was 150/90 mm Hg and apical heart rate was 148 beats/min on treatment with digoxin 125 μ g daily, frusemide 40 mg daily, enalapril 10 mg twice daily, nifedipine LA 30 mg daily, and warfarin. Serum creatinine was 308 μ mol/l. Renal ultrasonography showed a small left kidney (8.9 cm) and a normal size right kidney. Echocardiography revealed concentric left ventricular (LV) hypertrophy, no valve lesions and good LV function.

Coronary angiography revealed an 80% diffuse disease of the left anterior descending artery, and a 50% obtuse marginal stenosis. Renal angiography performed at the same time revealed total occlusion of the left renal artery and a proximal severe stenosis of a single right renal artery (fig). Enalapril was therefore discontinued and five days later serum creatinine fell to 148 μ mol/l.

Subsequently, blood pressure and symptoms of apparent heart failure were difficult to control despite adequate control of the atrial fibrillation. The patient was then started on losartan 50 mg twice daily in addition to two Frumil (co-amilofruse 5/40)

Aortography showing severe proximal renal artery stenosis in a single functioning kidney.

daily, doxazosin 4 mg daily, digoxin 250 µg daily and warfarin. However, there was only mild reduction in blood pressure (183/102 mm Hg), but rather surprisingly there was no deterioration in serum creatinine (175 µmol/l). A successful renal angioplasty was undertaken six months later.

This case confirms our previous observation where, in hypertensive patients with renal impairment, unilateral stenosis in a single functioning kidney may cause apparent congestive heart failure in the absence of overt left ventricular dysfunction or valvar heart disease.² The observation that renal function deteriorated with an ACE inhibitor, but not with an AII receptor antagonist, is of interest as we are unaware of any other reports.

CONSTANTINOS G MISSOURIS
DAVID E WARD
JOHN B EASTWOOD
GRAHAM A MACGREGOR
Department of Cardiology, Department of Renal
Medicine, and Blood Pressure Unit,
Department of Medicine,
St George's Hospital Medical School,
Cranmer Terrace, London SW17 0RE,
United Kingdom

1 Hricik DE, Browing PJ, Kopelman R, Goorno WE, Madias NE, Dzau VJ. Captopril induced functional renal insufficiency in patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney. *N Engl J Med* 1983;308:373-6.

2 Missouris CG, Buckenham T, Vallance PJT, MacGregor GA. Renal artery stenosis masquerading as congestive heart failure. *Lancet* 1993;341:1521-2.

Stability of plasma concentrations of N- and C-terminal atrial natriuretic peptides at room temperature

SIR,—In their study of the stability of N- and C-terminal atrial natriuretic peptides (ANP) Cleland *et al*¹ compared the storage of samples at -20°C and -70°C. They found no difference between plasma C-terminal ANP concentrations when the samples were centrifuged immediately and stored at -70°C or -20°C, or if kept at room temperature as whole blood for six hours or plasma for up to 24 hours.

Dr Cleland also examined the role of aprotinin (Trasylol) in sample preservation. The addition of aprotinin to the sample made no difference to the N-terminal ANP concentration, but the effect on the C-terminal ANP concentration is not documented.

The stability of ANP in whole blood. The effect of time and aprotinin

Whole blood	Time (hours)	With aprotinin	Without aprotinin
Room temperature	1	87%	86%
	2	80%	75%
	3	60%	64%
At 0°C	1	90%	87%
	2	84%	83%
	3	—	78%

Results are expressed as percentage of the original ANP concentration (n = 5). Recovery of ANP when processed immediately is > 96%.

In our own investigations we examined the effect of delayed separation where the sample, collected into polypropylene tubes containing EDTA, with and without the addition of aprotinin, was maintained as whole blood at room temperature and at 0°C for one to three hours.

Plasma ANP levels were measured by radioimmunoassay following Sep-pak plasma extraction as previously described.² The results demonstrated that the addition of aprotinin made little difference to the plasma concentration of the C-terminal ANP (table).

G MCDOWELL
C SHAW
KD BUCHANAN
DP NICHOLLS
Royal Victoria Hospital,
Grosvenor Road,
Belfast, BT12 6BA, United Kingdom

1 Cleland JGF, Ward S, Dutka D, Habib F, Impallomeni M, Morton IJ. Stability of plasma concentrations of N and C terminal atrial natriuretic peptides at room temperature. *Heart* 1996;75:410-13.

2 Nugent AM, Onuoha GN, McEneaney DJ, Steele IC, Hunter SJ, Prasanna R, *et al*. Variable patterns of atrial natriuretic peptide secretion in man. *Eur J Clin Invest* 1994; 24:267-74.

NOTICES

An Introduction to Vascular Biology will be held at St Thomas' Hospital, London, United Kingdom on 8-9 May, 1997. For further information, please contact the Secretariat, Hampton Medical Conferences, 127 High Street, Teddington, Middlesex TW11 8HH. (Tel: 0181 977 0011; fax: 0181 977 0055).

The 1997 Cardiology for Consultants weekend symposium designed for consultants and doctors training in cardiology is to be held at Exeter College, Oxford from 4-6 July, 1997. All conference costs and accommodation are covered by an educational grant from Bayer plc. A booking fee of £50 (cheque made payable to BHF) is refundable at the symposium. For an application form please telephone +(0) 1291 672528.

The International Congress of Cardiac Imaging will be held at the Queen Mother Conference Centre, Edinburgh from 1-3 September, 1997. For further information, please contact Helen Wilde, 6 Napier Road, Redland, Bristol, United Kingdom. (Tel/fax: +(0) 117 9739746; e-mail: m.rees@bris.ac.uk) or visit <<http://www.his.path.cam.ac.uk/rad/radiol/html>> on the Internet.

The 70th European Atherosclerosis Society Congress will be held in Jerusalem, Israel from 6-9 September, 1998. For further information please contact Professor Yechezkiel Stein, 70th EAS Congress, POB 50006, Tel Aviv 61500, Israel. (Tel: +972 3 5140014; fax: +972 3 5175674/5140077.)